Welcome to our dedicated page for Kodiak Sciences news (Ticker: KOD), a resource for investors and traders seeking the latest updates and insights on Kodiak Sciences stock.
Kodiak Sciences Inc. (Nasdaq: KOD) is a precommercial, retina-focused biotechnology company whose news flow centers on clinical trial progress, scientific data presentations and capital markets activity. The company is developing biologic therapeutics for retinal vascular diseases and macular edema secondary to inflammation (MESI), built on its proprietary ABC Platform and late-stage programs tarcocimab, KSI-501 and KSI-101.
On this page, readers can follow news about Kodiak’s Phase 3 studies, including GLOW2 in diabetic retinopathy, DAYBREAK in wet age-related macular degeneration, and the PEAK and PINNACLE studies in MESI. Company press releases describe milestones such as completion of enrollment in pivotal trials, new data from the Phase 1b APEX study of KSI-101, and updates on the performance of tarcocimab and KSI-501 in retinal vascular indications.
Kodiak Sciences also issues news about participation in major scientific and investor conferences, where its management and clinical collaborators present data on retinal programs and discuss the potential of IL-6 and VEGF targeting in eye disease. In addition, investors will find announcements related to public offerings of common stock and other financing activities, which the company uses to support its late-stage development and manufacturing efforts.
For anyone tracking KOD stock or developments in retinal biotechnology, this news feed offers a centralized view of Kodiak Sciences’ clinical, scientific and corporate updates as it advances its portfolio of investigational retinal medicines.
Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical firm focused on retinal diseases, will present at two virtual investor conferences: the Citi 15th Annual BioPharma Conference on September 10 at 9:35 a.m. PT and the Morgan Stanley 18th Annual Global Healthcare Conference on September 17 at 10:15 a.m. PT. Webcasts of these presentations will be available on Kodiak's website, along with a limited-time replay option. Kodiak is advancing therapies aimed at preventing blindness caused by retinal conditions using its proprietary ABC Platform™.
Kodiak Sciences Inc. (Nasdaq: KOD) reported its Q2 2020 results, highlighting significant advancements in their KSI-301 program targeting retinal diseases. CEO Victor Perlroth noted robust enrollment in the DAZZLE study for wet AMD, with 375 patients enrolled as of July 30, 2020. The company has a strong cash position of $417.1 million, but reported a net loss of $26 million. Increased R&D expenses of $20.6 million reflect ongoing clinical development. Kodiak remains on track for pivotal study initiations in 2020 and aims for a BLA submission in 2022.
Kodiak Sciences Inc. (Nasdaq: KOD) announced an R&D webcast on July 27, 2020, to discuss safety, efficacy, and durability data from its ongoing Phase 1b study of KSI-301 in treating retinal diseases like wet AMD, DME, and RVO. Management will review progress on the pivotal DAZZLE study in treatment-naïve wet AMD patients and planned pivotal studies for other conditions. KSI-301 aims to improve treatment outcomes and prevent vision loss in these diseases.
Kodiak Sciences (Nasdaq: KOD) announced positive data from its Phase 1b study of KSI-301, an anti-VEGF therapy for retinal diseases. Over 100 patient-years of data confirm KSI-301's safety and efficacy, with 82% of wet AMD and 76% of DME patients remaining treatment-free for four months post-initial doses. The therapy showed limited intraocular inflammation with significant vision improvements. Kodiak plans further pivotal studies in DME, RVO, and diabetic retinopathy, targeting a BLA submission by 2022, underpinned by strong clinical support and community engagement.
Kodiak Sciences Inc. (Nasdaq: KOD) announced that new data from the ongoing Phase 1b study of KSI-301, a novel anti-VEGF antibody biopolymer conjugate, will be presented at the ASRS 2020 Virtual Annual Meeting. The presentation will take place on July 10, 2020, showcasing results from 121 patients with wet AMD, diabetic macular edema, and retinal vein occlusion. CEO Victor Perlroth highlighted the promising safety and efficacy data accumulated across over 150 patient-years. A related R&D webinar is set for July 27, 2020, to discuss the implications of these findings.